S-ethyl O-(5,5-bis(diethylphosphono)pentanoyloxy)methyl carbonothioate | 947537-45-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: S-ethyl O-(5,5-bis(diethylphosphono)pentanoyloxy)methyl carbonothioate
• 英文别名: S-Ethyl O-(5,5-bis(diethylphosphono)pentanoyloxy)methyl carbonothioate；ethylsulfanylcarbonyloxymethyl 5,5-bis(diethoxyphosphoryl)pentanoate
• CAS: 947537-45-3
• 化学式: C₁₇H₃₄O₁₀P₂S
• 分子量: 492.464
• InChiKey: ZBGYJMBETKOPQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  30
• 可旋转键数：
  20
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  149
• 氢给体数：
  0
• 氢受体数：
  11

反应信息

• 作为反应物：
  描述：

  S-ethyl O-(5,5-bis(diethylphosphono)pentanoyloxy)methyl carbonothioate 在 磺酰氯 、 1,8-双二甲氨基萘 作用下， 以 四氢呋喃 为溶剂， 生成
  参考文献：
  名称：

  PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS

  摘要：

  本发明涉及磷酸化利福霉素以及制备和使用这类化合物的方法。这些化合物可用作预防和/或治疗骨骼和关节感染的抗生素，特别是用于预防和/或治疗骨髓炎。

  公开号：

  US20110263534A1
• 作为产物：
  描述：

  tetraethyl (5-hydroxypentylidene)bisphosphonate 在 2,2,6,6-tetramethyl-piperidine-N-oxyl sodium hypochlorite 、 sodium chlorite 、 四丁基硫酸氢铵 、 碳酸氢钠 作用下， 以 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 7.0h， 生成 S-ethyl O-(5,5-bis(diethylphosphono)pentanoyloxy)methyl carbonothioate
  参考文献：
  名称：

  PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS

  摘要：

  本发明涉及磷酸化利福霉素以及制备和使用这类化合物的方法。这些化合物可用作预防和/或治疗骨骼和关节感染的抗生素，特别是用于预防和/或治疗骨髓炎。

  公开号：

  US20110263534A1

文献信息

• PHOSPHONATED GLYCOPEPTIDE AND LIPOGLYCOPEPTIDE ANTIBIOTICS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS
  申请人：Tanaka Kelly

  公开号：US20100113333A1

  公开（公告）日：2010-05-06

  The present invention is directed to antimicrobial compounds which have an affinity for binding bones. More particularly, the invention is directed to phosphonated derivatives of glycopeptide or lipoglycopeptide antibiotics. These compounds are useful as antibiotics for the prevention or treatment of bone and joint infections, especially for the prevention and treatment of osteomyelitis.

  本发明涉及具有结合骨头亲和力的抗微生物化合物。更具体地说，本发明涉及糖肽或脂肽糖肽抗生素的膦酸衍生物。这些化合物可用作抗生素，用于预防或治疗骨和关节感染，特别是用于预防和治疗骨髓炎。
• Phosphonated glycopeptide and lipoglycopeptide antibiotics and uses thereof for the prevention and treatment of bone and joint infections
  申请人：Tanaka Kelly

  公开号：US08946144B2

  公开（公告）日：2015-02-03

  The present invention is directed to antimicrobial compounds which have an affinity for binding bones. More particularly, the invention is directed to phosphonated derivatives of glycopeptide or lipoglycopeptide antibiotics. These compounds are useful as antibiotics for the prevention or treatment of bone and joint infections, especially for the prevention and treatment of osteomyelitis.

  本发明涉及具有结合骨头亲和力的抗微生物化合物。更具体地说，本发明涉及糖肽或脂肽糖肽抗生素的膦酸衍生物。这些化合物可用作预防或治疗骨和关节感染的抗生素，尤其是预防和治疗骨髓炎。
• Phosphonated Rifamycins and uses thereof for the prevention and treatment of bone and joint infections
  申请人：Rose Yannick Stephane

  公开号：US08404664B2

  公开（公告）日：2013-03-26

  The present invention relates to phosphonated Rifamycins, and methods of making and using such compounds. These compounds are useful as antibiotics for prophylaxis and/or the treatment of bone and joint infections, especially for the prophylaxis and/or treatment of osteomyelitis.

  本发明涉及磷酸化利福霉素及其制备和使用方法。这些化合物可用作抗生素，用于预防和/或治疗骨和关节感染，特别是用于预防和/或治疗骨髓炎。
• Synthesis and in vitro evaluation of bisphosphonated glycopeptide prodrugs for the treatment of osteomyelitis
  作者：Kelly S.E. Tanaka、Evelyne Dietrich、Stéphane Ciblat、Claude Métayer、Francis F. Arhin、Ingrid Sarmiento、Gregory Moeck、Thomas R. Parr、Adel Rafai Far

  DOI：10.1016/j.bmcl.2010.01.006

  日期：2010.2

  As therapeutic agents of choice in the treatment of complicated infections, glycopeptide antibiotics are often preferentially used in cases of osteomyelitis, an infection located in bone and notoriously difficult to successfully manage. Yet frequent and heavy doses of these systemically administered antibiotics are conventionally prescribed to obtain higher antibiotic levels in the bone and reduce the high recurrence rates. Targeting antibiotics to the bone after systemic administration would present at least three potential advantages: (i) greater efficacy, by concentrating the therapeutic agent in bone; (ii) greater convenience, through a reduction in the frequency of administration; and (iii) greater safety, by reducing the levels of systemic drug exposure. We present here the design, synthesis and in vitro evaluation of eight prodrugs of the glycopeptide antibacterial agents vancomycin and oritavancin taking advantage of the affinity of the bisphosphonate group for bone for delivery to osseous tissues. (C) 2010 Elsevier Ltd. All rights reserved.